FINNENCE ▪ THE WIRE FILE
THE WIRE · № 61914
News■ Unclear/unknown
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 13:06 UTC
LAST UPDATE2026-10-02 13:06 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A conference presentation announcement reveals no clinical or financial data.
Routine disclosure, no investable content
CATALYST TO WATCH
Data presented at EADV
MAIN RISK
No efficacy or revenue detail given
FULL DISPATCH
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
←CORRELATIONshares Healthcare
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
←CORRELATIONshares Healthcare
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
←CORRELATIONshares Healthcare
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
←CORRELATIONshares Healthcare
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.